Oragenics to Participate in the 2022 BioFlorida Annual Conference
Oragenics, Inc. OGEN ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being held November 2-4 in Miami.
Kim Murphy, President and CEO, will be participating on a panel titled "BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases" on Thursday, November 3 from 2:05 p.m. to 3:05 p.m.
|
Panel: |
BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases |
||
|
Date: |
Thursday, November 3, 2022 |
||
|
Time: |
2:05 p.m. Eastern Time |
||
|
Location: |
Hyatt Regency Miami |
Ms. Murphy will also be participating in BioFlorida's one-on-one investor and business development meetings. Please contact LHA Investor Relations to schedule a meeting.
About Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information about Oragenics, please visit www.oragenics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005965/en/
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
